Skip to main content

Table 3 Enrolment number and publishing timeline for completed studies

From: Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009

Registration number

Type of study

Treatment

Planned enrolment (n)

Total patients1 (n)

H1N1 patients1 (n)

First patient enrolment1 (month, year)

Last patient enrolment1 (month, year)

Date published (month, year)

Enrolment commenced before pandemic

 NCT00298233

Phase 2

Oseltamivir

400

326

72

Apr. 2007

Feb. 2010

May 2013 [8]

 NCT00391768

Phase 1/2

Oseltamivir

108

87

37

Jan. 2007

Apr. 2010

Mar. 2013 [9]

Enrolment commenced during pandemic

 NCT00949533

Phase 3

Oseltamivir

125

37

Unknown

Aug. 2009

Oct. 2010

Apr. 2016 (Unp)

 NCT00957996

Phase 3

Peramivir

300

127

94

Oct. 2009

Oct. 2010

Aug. 2013 [10]

 NCT01199744

Prospective cohort

Zanamivir

N/R

1575

Unknown

Nov. 2009

Apr. 2010

Mar. 2011(Unp)

 NCT01014988

Phase 2

Zanamivir

150

130

92

Nov. 2009

Sep. 2011

Feb. 2014 [11]

 NCT01052961

Phase 4

Oseltamivir

400

155

34

Jan. 2010

Jun. 2012

Dec. 2013 [12]

 NCT01050257

Phase 3

Oseltamivir

200

118

Unknown

Jan. 2010

Sep. 2012

Aug. 2013 (Unp)

 NCT01068912

Phase 2

Favipiravir

384

530

110

Feb. 2010

May 2012

Feb. 2014 (Unp)

  1. Enrolment number and publishing timeline for completed studies where results are published in the literature (date followed by reference) or on the clinical trials registration site (date followed by Unp)
  2. N/R not reported
  3. 1Where conflict existed between numbers in the clinical trial record and publication, publication numbers were used